In our study, we observed that low level expressions of ADGRA2 or ADRB3 increased the pCR rate in the NACBC validation and GEO sets, suggesting a negative correlation between ADGRA2 or ADRB3 amplification and NAC response in BC. Here, ADRB3 is linked to breast cancer.